Status | Study |
Not yet recruiting |
Study Name: Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Condition: Uveal Melanoma Date: 2017-02-14 Interventions: Biological: IMCgp100 IMCgp100 |
Not yet recruiting |
Study Name: Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Condition: Uveal Melanoma Date: 2016-12-21 Interventions: Drug: Vorinostat Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic ev |
Recruiting |
Study Name: Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis Condition: Uveal Melanoma Date: 2016-09-09 Interventions: Procedure: SIRT catheter-based |
Active, not recruiting |
Study Name: Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Condition: Uveal Melanoma Date: 2016-07-21 Interventions: Drug: Adjuvant chemotherapy by Fotemustin |
Recruiting |
Study Name: Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Condition: Uveal Melanoma Date: 2016-07-13 Interventions: Biological: Blood sampling 7,5 ml of patient peripherical blood will be collected at each blood sample. |
Recruiting |
Study Name: Intermittent Selumetinib for Uveal Melanoma Condition: Uveal Melanoma Date: 2016-05-10 Interventions: Drug: Selumetinib 100mg, 125mg, 150mg, 175mg, 200mg or 225 |
Active, not recruiting |
Study Name: Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Condition: Uveal Melanoma Date: 2015-12-01 Interventions: Drug: ipilimumab Ipilimumab ev |
Recruiting |
Study Name: A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Condition: Uveal Melanoma Date: 2015-11-06 Interventions: Drug: LXS196 |
Recruiting |
Study Name: A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Condition: Uveal Melanoma Date: 2015-10-06 Interventions: Drug: IMCgp100 Bispecific soluble HLA-A2 restricted gp100-specific TCR fused to anti-CD3 |
Recruiting |
Study Name: Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Condition: Uveal Melanoma Date: 2014-08-20 Interventions: Drug: Crizotinib An anti-cancer drug acting as an ALK (ana |